Physician profile
Nadish Garg
NPI 1760594238
$17,492.49
in general payments reported to CMS, 2019-2025
29 companies · $4,933 in 2025
The $4,933 reported for 2025 was more than what 83% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,579 · 2020: $440 · 2021: $908 · 2022: $6,064 · 2023: $1,361 · 2024: $2,206 · 2025: $4,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,175 · Travel and Lodging: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,175.35 |
| Travel and Lodging | $1,325.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,911.35 | 2019-2025 | Mitraclip, Diamondback Peripheral, Advisor |
| Medtronic, INC. | $3,245.79 | 2021-2025 | Venaseal, Corevalve Evolut R, Micra |
| Edwards Lifesciences Corporation | $2,526.02 | 2019-2025 | Sapien 3 Ultra Resilia, Inspiris Resilia Aortic Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $2,088.40 | 2019-2025 | Watchman Flx, Emblem Mri S-Icd, Ekosonic |
| Cordis US Corp. | $1,148.66 | 2022 | |
| Abiomed | $771.20 | 2020-2025 | |
| Amgen INC. | $732.42 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $512.65 | 2022-2025 | |
| Medtronic Vascular, INC. | $416.37 | 2019-2020 | |
| Novo Nordisk INC | $280.44 | 2022-2025 | Wegovy, Ozempic |
| Philips North America LLC | $222.29 | 2019-2024 | (Bh4) Igt Devices Undivided |
| Inari Medical, INC. | $211.78 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.50 | 2022-2025 | Lifevest |
| Pfizer INC. | $189.71 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.60 | 2021-2024 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $164.74 | 2022-2024 | Verquvo |
| Penumbra, INC. | $149.67 | 2024 | Penumbra System |
| Shockwave Medical, INC | $124.40 | 2021 | |
| Imperative Care, INC | $91.94 | 2025 | Symphony Catheter |
| E.R. Squibb & Sons, L.L.C. | $88.61 | 2023-2024 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $78.69 | 2023 | Optimizer |
| Biosense Webster, INC. | $32.19 | 2025 | Nuvision Ice Catheter |
| Janssen Pharmaceuticals, INC | $28.74 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $28.17 | 2025 | |
| Becton, Dickinson and Company | $24.21 | 2025 | Powerglide |
| Lexicon Pharmaceuticals, INC. | $19.78 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $19.75 | 2024 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $17.42 | 2024 | Arcalyst |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadish Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.